TECN.SW Tecan Group AG (SIX) down 5% intraday Mar 13 2026: earnings ahead could reset the stock

TECN.SW stock opened lower on Mar 13 2026 and trades at CHF119.40 after a -5.01% intraday move. The drop follows market volatility ahead of Tecan Group AG’s earnings due on 16 Mar 2026. Investors will watch EPS of 4.95 and the company’s margins closely. Tecan Group AG (TECN.SW) is listed on the SIX exchange in Switzerland and has a market cap near CHF1.57B. For company details see the official site Tecan and its LinkedIn page Tecan LinkedIn.

Earnings catalyst and timing for TECN.SW stock

Tecan reports results on 16 Mar 2026, making this an intraday earnings spotlight. The market expects guidance on Partnering and Life Sciences segments. Current EPS is 4.95 and the trailing PE is 24.95, numbers investors will use to judge upside. Any guidance change could move shares sharply from CHF119.40.

Quick fundamentals snapshot and TECN.SW stock metrics

Tecan shows stable cash per share at 31.23 and book value per share at 100.85. The company trades below its 50-day average of 136.56 and 200-day average of 148.06. Dividend per share is 3.00, implying a yield near 2.39% at current price. Balance sheet metrics show a conservative debt to equity ratio of 0.25.

Valuation, price targets and Meyka AI grade for TECN.SW stock

Valuation metrics include a price to sales of 1.76 and EV/EBITDA of 12.52. Meyka AI rates TECN.SW with a score out of 100: 71.52 (Grade B+, Suggestion: BUY). This grade factors S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Price targets: conservative CHF100.00 (PE20), base CHF125.00 (PE25), bull CHF150.00 (PE30). Implied moves are -16.26%, +4.75%, and +25.63% respectively from CHF119.40.

Technical picture and market context for TECN.SW stock

Technicals show momentum weakness: RSI 36.11 and MACD negative. Volume at 14,849 trades below the 50-day average of 61,477. Healthcare peers trade at an average PE near 29.52, so Tecan is cheaper on PE. The stock is nearer its year low than its year high, with a year high of 181.70 and year low of 120.50 reported.

Earnings preview, forecasts and scenario planning for TECN.SW stock

Meyka AI’s forecast model projects a quarterly price of CHF120.29 and a yearly model price of CHF103.72. The quarterly projection implies upside of 0.75% versus current price. Analysts will watch revenue mix, margin trend, and Partnering order book disclosure. Scenarios: beat could push price above CHF130.00, a miss could revisit CHF100.00.

Risks, opportunities and sector positioning for TECN.SW stock

Key risks include softer lab spending and Partnering timing shifts that affect revenue recognition. Opportunities include growing demand for automation and NGS reagents in diagnostics. Tecan sits in Healthcare instruments, a sector with average PE 29.52, which supports premium re-rating if growth returns. Currency and supply-chain noise can add short-term volatility.

Final Thoughts

TECN.SW stock faces a pivotal earnings moment on 16 Mar 2026. At CHF119.40, the market prices a modest premium over model valuations near PE25. Meyka AI’s forecast model projects CHF120.29 over the next quarter, implying a small upside of 0.75%, while the one-year model at CHF103.72 implies downside near 13.13%. Our price-band scenario gives conservative, base, and bull targets of CHF100.00, CHF125.00, and CHF150.00 respectively. The Meyka grade of 71.52 (B+, BUY) balances solid cash generation, a controlled debt load, and sector comparatives. Watch reported EPS of 4.95, margin commentary, and order timing. Earnings beat and upgraded guidance could re-rate valuation toward the mid CHF130 area. Forecasts are model-based projections and not guarantees. For real-time monitoring use Meyka AI-powered market analysis tools and the Tecan site for filings Tecan.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.